Alprolix
eftrenonacog alfa
Table of contents
Overview
This is a summary of the European public assessment report (EPAR) for Alprolix. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Alprolix.
For practical information about using Alprolix, patients should read the package leaflet or contact their doctor or pharmacist.
-
List item
Alprolix : EPAR - Summary for the public (PDF/75.56 KB)
First published: 25/05/2016
Last updated: 25/05/2016
EMA/171272/2016 -
-
List item
Alprolix : EPAR - Risk-management-plan summary (PDF/105.11 KB)
First published: 10/04/2019
Last updated: 04/11/2020
Authorisation details
Product details | |
---|---|
Name |
Alprolix
|
Agency product number |
EMEA/H/C/004142
|
Active substance |
eftrenonacog alfa
|
International non-proprietary name (INN) or common name |
eftrenonacog alfa
|
Therapeutic area (MeSH) |
Hemophilia B
|
Anatomical therapeutic chemical (ATC) code |
B02BD04
|
Additional monitoring |
This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under additional monitoring. |
Orphan |
This medicine was designated an orphan medicine. This means that it was developed for use against a rare, life-threatening or chronically debilitating condition or, for economic reasons, it would be unlikely to have been developed without incentives. For more information, see Orphan designation. |
Publication details | |
---|---|
Marketing-authorisation holder |
Swedish Orphan Biovitrum AB (publ)
|
Revision |
5
|
Date of issue of marketing authorisation valid throughout the European Union |
12/05/2016
|
Contact address |
Product information
19/10/2020 Alprolix - EMEA/H/C/004142 - II/0029
Contents
- Annex I - Summary of product characteristics
- Annex IIA - Manufacturing-authorisation holder responsible for batch release
- Annex IIB - Conditions of the marketing authorisation
- Annex IIIA - Labelling
- Annex IIIB - Package leaflet
Please note that the size of the above document can exceed 50 pages.
You are therefore advised to be selective about which sections or pages you wish to print.
Pharmacotherapeutic group
-
Vitamin K and other hemostatics
-
Blood coagulation factors
Therapeutic indication
Treatment and prophylaxis of bleeding in patients with haemophilia B (congenital factor IX deficiency).